NAIROBI, Kenya Dec 9 – The government will implement a system to rapidly deploy essential drugs, vaccines, and diagnostic tools during national health emergencies by leveraging the regulatory approvals of the United States Food and Drug Administration (FDA).
This mechanism is a core component of the new Cooperation Framework between Kenya and the United States on Health.
The primary objective of the provision is to drastically reduce the time taken to introduce life-saving medical countermeasures during a disease outbreak.
This strategic alignment supports Kenya’s ambitious goal to meet the 7-1-7 public health metric a global benchmark requiring a country to detect an outbreak within 7 days, notify authorities within 1 day, and complete the initial response within 7 days.
Expedited Approval Mechanism
The Framework outlines that the U.S. FDA’s clearance for emergency use of a medical product will serve as the primary evidence needed for its deployment in Kenya.
“The Government of Kenya intends to allow the United States Food and Drug Administration’s (FDA) approval or Emergency Use Authorization of medical countermeasures to be a sufficient basis to use the medical countermeasures to respond to an outbreak in the country in accordance with applicable legislation in Kenya,” the agreement read.
This means that instead of conducting a full, time-consuming scientific review, the Kenya Pharmacy and Poisons Board (PPB) can rely on the FDA’s judgment and move quickly to complete the necessary administrative and legal steps for use, ensuring the public gains immediate access to vital tools.
Crucially, the agreement stresses that the use of these fast-tracked products remains subject to our applicable laws this ensures that the process must align with Kenyan public health laws and safety requirements, preserving the legal authority of local regulatory bodies.
“The U.S. Government, in coordination with the Government of Kenya, intends to establish a funding mechanism to surge additional personnel, supplies, equipment and other necessary materials… to respond to detected infectious disease threats… and implemented according to applicable laws and regulations of the Republic of Kenya,”the agreement read.
System Strengthening
This regulatory mechanism is part of a larger plan to enhance domestic health security capabilities. The Framework specifies significant institutional build-up, including the operationalization of the Kenya National Public Health Institute (KNPHI) and the establishment of 10 KNPHI Regional Hubs and 20 County Emergency Operation Centers.
By adopting this system, the Ministry of Health aims to ensure that infrastructure investments are matched by operational efficiency, allowing the country to transition from prolonged reliance on donor assistance to self-sustaining national capacity for disease prevention and rapid response.
This provision has immediate and critical implications for how Kenya sources vital supplies including vaccines during a major health crisis.
By recognizing the FDA’s emergency authorization as sufficient for use in Kenya, the framework streamlines the import and deployment of American-developed or U.S.-based pharmaceutical products.
During the scarcity of the COVID-19 pandemic, countries that relied on the FDA for validation often found themselves in direct competition for the same limited supply chains.
Analysis shows that in a crisis, a reliance on the FDA’s decision-making process inherently prioritizes products that meet U.S. standards and market access.
This could put Kenya at a significant disadvantage if the most readily available or affordable vaccine during a crisis originates from a non-U.S. source (such as China, India, or Europe) that has not yet secured FDA approval, or if the U.S. implements export restrictions on its approved countermeasures.